Rational use of oral antibiotics in adults and school children (from the age of 6 years). Recommendations of an expert committee of the Paul Ehrlich Society for Chemotherapy;Rationaler einsatz oraler antibiotika bei erwachsenen und schulkindern (lebensalter ab 6 jahre). Empfehlungen einer expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V.

Chemotherapie Journal

Volumn 15, Issue 5, 2006, Pages 129-144

  Stahlmann, Ralf ^a   Lode, Hartmut ^a   Skopnik, Heino ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinikum Worms   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZIDOCILLIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFADROXIL; CEFALEXIN; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DICLOXACILLIN; FLUCLOXACILLIN; FOSFOMYCIN; KETOLIDE; LORACARBEF; MACROLIDE; NITROFURANTOIN; NITROIMIDAZOLE; NORFLOXACIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TETRACYCLINE; UNINDEXED DRUG;

ALLERGIC REACTION; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ATAXIA; BACTERIAL INFECTION; CHLAMYDIASIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; DRUG USE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; IN VITRO STUDY; LIVER TOXICITY; LUNG FIBROSIS; MEDICAL EXPERT; MEDICAL PRACTICE; MEDICAL SOCIETY; NEUROPATHY; PATIENT COMPLIANCE; REVIEW; RISK FACTOR; SCHOOL CHILD; SEROTONIN SYNDROME; SYSTEMATIC REVIEW; TASTE DISORDER; VERTIGO; VIRUS INFECTION; WOUND INFECTION;

EID: 33750490788     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Adam D, Doerr HW, Link H, Lode H. Die Infektiologie. Heidelberg, Berlin, New York: Springer, 2005.
2. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2003. Antiinfectives Intelligence, Bonn, 2004.
3. Scholz H, Naber KG, et al. Einteilung der Cephalosporine. Chemother J 1999;6:227-30.
4. Schwabe U, Paffrath D (Hrsg.). Arzneiverordnungs-Report 2005. Berlin, Heidelberg, New York: Springer-Verlag, 2006.
5. Stahlmann R, Lode H. Antibiotika und Chemotherapeutika. Antiinfektiöse Therapie (Kapitel 36). In: Aktories K, Förstermann U, Hofmann F, Starke K (eds.). Begründet von Forth W, Henschler D, Rummel W. Allgemeine und spezielle Pharmakologie und Toxikologie. 9. Auflage. München, Jena: Urban & Fischer, 2004:781-919.
6. Stahlmann R, Lode H. Antibakterielle Chemotherapie. In: Steinbeck G, Paumgartner G (eds.). Therapie innerer Krankheiten. 11. Auflage. Berlin: Springer 2005:1680-703.
7. Stille W (Hrsg.). Antibiotika-Therapie, Klinik und Praxis der antiinfektiösen Behandlung. 11. Auflage. Stuttgart, New York: Schattauer Verlag, 2005.
8. Vogel F, Naber K, Wacha H, Shah P. Parenterale Antibiotika bei Erwachsenen. Chemother J 1999;1:3-49.
9. Vogel F, Worth H, Adam D, Elies W, et al. Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe der Paul-Ehrlich- Gesellschaft für Chemotherapie e. V. und der Deutschen Atemwegsliga e. V. Chemother J 2000;9:3-23.
10. Deutsche Gesellschaft für pädiatrische Infektiologie (Hrsg.). Handbuch Infektionen bei Kindern und Jugendlichen. 4. Auflage. München: Futuramed Verlag, 2003.
11. Scholz H, Vogel F, et al. Rationaler Einsatz oraler Antibiotika bei Kindern und Jugendlichen. Chemother J 2002;11:59-70.
12. Stahlmann R. Children as a special population at risk - quinolones as an example for xenobiotics exhibiting skeletal toxicity. Arch Toxicol 2003;77:7-11.
13. Adriaenssen CF. Comparison of the efficacy, safety and tolerability of azithromycin and coamoxiclav in the treatment of acute periapical abscesses. J Int Med Res 1998;26:257-65.
14. Brennan MT, Runyon MS, Batts JJ, Fox PC, et al. Odontogenic signs and symptoms as predictors of odontogenic infection: a clinical trial. J Am Dent Assoc 2006;137:62-6.
15. Epstein JB, Chong S, Le ND. A survey of antibiotic use in dentistry. J Am Dent Assoc 2000;131:1600-9.
16. Keenan JV, Farman AG, Fedorowicz Z, Newton JT. Antibiotic use for irreversible pulpitis. Cochrane Database Syst Rev 2005(2): CD004969.
17. Lamey PJ, Boyle MA, MacFarlane TW, Samaranayake LP. Acute suppurative parotitis in outpatients: microbiologic and posttreatment sialographic findings. Oral Surg Oral Med Oral Pathol 1987;63:37-41.
18. Lo Bue AM, Sammartino R, Chisari G, Gismondo MR, et al. Efficacy of azithromycin compared with spiramycin in the treatment of odontogenic infections. J Antimicrob Chemother 1993;31(Suppl E):119-27.
19. Morse DR, Furst ML, Belott RM, Lefkowitz RD, et al. Infectious flare-ups and serious sequelae following endodontic treatment: a prospective randomized trial on efficacy of antibiotic prophylaxis in cases of asymptomatic pulpal-periapical lesions. Oral Surg Oral Med Oral Pathol 1987;64:96-109.
20. Panattoni E, Marcucci M, Gabriele M, Natale ML, et al. The clinical efficacy of roxithromycin in patients with acute odontogenic infections. Minerva Stomatol 1991;40:273-6.
21. Morse DR, Furst ML, Belott RM, Lefkowitz RD, et al. Prophylactic penicillin versus penicillin taken at the first sign of swelling in cases of asymptomatic pulpal-periapical lesions: a comparative analysis. Oral Surg Oral Med Oral Pathol 1988;65:228-32.
22. Adam D, Scholz HS, Helmerking M. Short-course antibiotic treatment of 4 782 culture-proven cases of group A streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. J Infect Dis 2000;182:509-16.
23. Axelsson A, Jensen C, Melin O, Singer F, et al. Treatment of acute maxillary sinusitis. V. Amoxicillin azidocillin, phenylpropanolamine and pivampicillin. Acta Otolaryngol 1981;91: 313-8.
24. van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, Peeters MF. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. Lancet 1997;349:683-7.
25. Camacho AE, Cobo R, Otte J, Spector SL, et al. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992;93:271-6.
26. Chatzimanolis E, Marsan N, Lefatzis D, Pavlopoulos A. Comparison of roxithromycin with coamoxiclav in patients with sinusitis. J Antimicrob Chemother 1998;41(Suppl B):81-4.
27. Elies W, Huber K. Short-course therapy for acute sinusitis: how long is enough? Treat Respir Med 2004;3:269-77.
28. Hayle R, Lingaas E, Hoivik HO, Odegard T. Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1996;15:849-53.
29. Henry DC, Sydnor A Jr., Settipane GA, Allen J, et al. Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitis. Clin Ther 1999;21:1158-70.
30. Klapan I, Culig J, Oreskovic K, Matrapazovski M, et al. Azithromycin versus amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 1999;20:7-11.
31. Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ 1996;313:325-9.
32. Siegert R, Gehanno P, Nikolaidis P, Bagger-Sjoback D, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94:337-44.
33. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:77-120.
34. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
35. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
36. Ball P, Make B. Acute exacerbation of chronic bronchitis: An international comparison. Chest 1998;113(Suppl):S199-204.
37. Bartlett JG, Dowell SF, Mandell LA, File TM, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82.
38. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 2005;128:2230-7.
39. Höffken G, Lorenz J, Kern W, Welte T, et al. Leitlinie der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG), der Deutschen Gesellschaft für Pneumologie (DGP), der Deutschen Gesellschaft für Infektiologie (DGI) und vom Kompetenznetzwerk CAPNETZ zu Epidemiologie, Diagnostik, antimikrobieller Therapie und Management von erwachsenen Patienten mit ambulant erworbenen tiefen Atemwegsinfektionen (akute Bronchitis, akute Exazerbation einer chronischen Bronchitis, Influenza und andere respiratorische Virusinfektion) sowie ambulant erworbener Pneumonie. Chemother J 2005;14:97-155.
40. Mandell LA, Marrie TJ, Grossman RF, Chow AW, et al. Summary of Canadian guidelines of the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society. Can Respir J 2000;7:371-82.
41. Vanderkooi OG, Low DE, Green K, Powis JE, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005;40:1288-97.
42. Adam D, Bodmann KF, Elies W, et al. Behandlung von Infektionen der Gallenblase und der Gallenwege. Arzneimitteltherapie 2006;24:43-9.
43. American Society for Gastrointestinal Endoscopy. Guidelines for antibiotic prophylaxis for GI endoscopy. Gastrointest Endoscop 2003;58:475-82.
44. Harris A, Chan AC, Torres-Viera C. Hammett R, et al. Meta-analysis of antibiotic prophylaxis in endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 1999;31:718-24.
45. Thompson BF, Arguedas MR, Wilcox CM. Antibiotic prophylaxis prior to endoscopic retrograde cholangiopancreatography in patients with obstructive jaundice: is it worth the cost? Aliment Pharmacol Ther 2002;16:727-34.
46. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001;17:331-41.
47. Naber KG, Bishop MC, Bjerklund-Johansen TE, et al. EAU Guidelines on the management of urinary and male genital tract infections. European Association of Urology; www.uroweb.org (〉publications〉online guidelines) March 2006.
48. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Eur Urology 2001;40:576-88.
49. Warren JW, Abrutyn E, Hebel JR, Johnson JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 1999;29:745-58.
50. Friese K, Schäfer A, Hof H. Infektionskrankheiten in der Gynäkologie und Geburtshilfe. Berlin, Heidelberg, New York: Springer, 2003.
51. Kohl PK. Gonorrhoe und andere Formen der Urethritis. In: Braun-Falco O, Plewig G. Wolff HH, Burgdorf WHC, Landthaler M (Hrsg.). Dermatologie und Venerologie. Berlin, Heidelberg, New York: Springer, 2005:215-26.
52. Petersen EE. Infektionen in Gynäkologie und Geburtshilfe. 4. Auflage. Stuttgart, Thieme, 2003.
53. Petzold D. Syphilis. In: Braun-Falco O, Plewig G. Wolff HH, Burgdorf WHC, Landthaler M (Hrsg.). Dermatologie und Venerologie. Berlin, Heidelberg, New York: Springer, 2005:227-44.
54. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol 1994;171:1215-20.
55. Tietz JJ, Mendling W. Haut- und Vaginalmykosen. Berlin: Blackwell, 2001.
56. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005;366:1725-35.
57. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. Int J Antimicrob Agents 2005;26:357-65.
58. Gross G, Jansen T, Kujath P, Plewig G. Haut- und Weichteilinfektionen. In: Adam D, Doerr HW, Link H, Lode H (Hrsg.). Die Infektiologie. Berlin, Heidelberg, New York: Springer. 2005:438-68.
59. Lipsky BA, Berendt AR, Deery HG, Embil JM, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004;39:885-910.
60. Talan DA, Abrahamian FM, Moran GJ, Citron DM, et al.: Emergency Medicine Human Bite Infection Study Group. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis 2003;37:1481-9.